Lanreotide Acetate and Prochlorperazine Edisylate

• Generic Name: lanreotide
• Dosage Forms: n.a.
• Other Brand Names: Somatuline Depot

Long-term treatment of acromegaly in patients who have had inadequate responses to or are not candidates for surgical resection and/or radiotherapy (designated an orphan drug by FDA for this use).

Goal of therapy is to normalize concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).

Improves certain manifestations of acromegaly (asthenia, joint pain, swelling of extremities, excessive perspiration, headache).

• Generic Name: prochlorperazine
• Dosage Forms: n.a.
• Other Brand Names: Compazine, Compro

Symptomatic management of psychotic disorders (i.e., schizophrenia).

Short-term management of nonpsychotic anxiety.

Efficacy established in patients with generalized anxiety disorder; not established whether prochlorperazine is useful for the management of other nonpsychotic conditions in which anxiety or manifestations that mimic anxiety are evident (e.g., physical illness, organic mental conditions, agitated depression, character pathologies).

Because of the risks of toxicity, use only as an alternative to other less toxic anxiolytic agents (e.g., benzodiazepines) in most patients.

Management of severe nausea and vomiting of various etiologies (e.g., postoperative, acute migraine, toxins, radiation, or cytotoxic drugs).

Not effective in preventing vertigo or motion sickness, or for the management of emesis caused by the action of drugs on the nodose ganglion or locally on the GI tract.

Use not recommended for the prevention and treatment of nausea and vomiting associated with pregnancy except in cases of severe nausea and vomiting so serious and intractable that pharmacologic intervention is required and the potential benefits justify the possible risks to the fetus. (See Fetal/Neonatal Morbidity under Cautions.)

Has not been shown to be effective for the management of behavioral complications in patients with mental retardation.